Suzuken (9987) Q2 2026 earnings summary

Executive summary

• Revenue and operating profit increased year-over-year, driven by growth in specialty drug distribution contracts and cost control measures, despite a decline in COVID-19-related product sales.

• Strategic focus on ambidextrous management, digital transformation, and capital efficiency, aiming for ROE over 8% for two consecutive years.

• Continued investment in digital healthcare, smart logistics, and new business models to reinforce the health creation enterprise vision.

• The company advanced its medium-term management plan, focusing on reforming existing businesses and preparing for new growth, including digital health and specialty drug distribution.

Financial highlights

• Consolidated net sales for 2Q FY2025 were ¥1,219.4 billion, up 1.8% year-over-year.

• Operating profit was ¥16.96 billion, with a margin of 1.39%.

• Ordinary profit rose to ¥18.03 billion, up 6.0% year-over-year.

• Profit attributable to owners of parent was ¥16.24 billion, down 19.9% year-over-year due to a high prior-year base and higher costs.

• Recorded a ¥5.2 billion gain from the sale of cross-held securities.

Outlook and guidance

• Targets for FY2025 include a consolidated operating profit margin of 1.5% or more and specialty drug net sales of ¥240 billion or more.

• Full-year net sales forecast is ¥2,468,000 million, up 2.8% year-over-year.

• Operating profit is projected to decline 9.5% to ¥33,600 million, and profit attributable to owners of parent is expected to fall 4.9% to ¥32,800 million.

• Annual dividend forecast is unchanged at ¥100 per share.

• Continued focus on digital healthcare monetization and expansion of the COLLABO Portal user base.